FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale

FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale

BackgroundTreatment options for poorly differentiated (PDTC) and anaplastic (ATC) thyroid carcinoma are unsatisfactory and prognosis is generally poor. Lenvatinib (LEN), a multi-tyrosine kinase inhibitor targeting fibroblast growth factor receptors (FGFR) 1-4 is approved for advanced radioiodine ref...

Full description

Bibliographic Details
Main Authors: Pia Adam, Stefan Kircher, Iuliu Sbiera, Viktoria Florentine Koehler, Elke Berg, Thomas Knösel, Benjamin Sandner, Wiebke Kristin Fenske, Hendrik Bläker, Constantin Smaxwil, Andreas Zielke, Bence Sipos, Stephanie Allelein, Matthias Schott, Christine Dierks, Christine Spitzweg, Martin Fassnacht, Matthias Kroiss
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Endocrinology
Subjects:
tyrosine kinase inhibitor (TKI)
immune checkpoint inhibitor (ICI)
immunohistochemistry
immunotherapy
PD-L1
FGFR
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.712107/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2021.712107/full

Similar Items